Navigation Links
Corporate Benefit Executives Identify Ways to Curb Prescription Drug Prices
Date:12/18/2007

Annual Arxcel study reveals that corporate benefit executives blame high

prescription costs on drug manufacturers

WILLIAMSVILLE, N.Y., Dec. 18 /PRNewswire/ -- Corporate benefit executives identified ways to curb high prescription drug costs in the 2007 Arxcel Prescription Benefit Research Survey. And, drug manufacturers are to blame for the high cost of prescription benefit programs, according to 70 percent of survey respondents.

Each year, prescription benefit management consultancy Arxcel (http://www.arxcel.com) commissions its annual Prescription Benefit Research Survey, gathering perceptions from leading benefit managers and HR executives nationwide regarding factors contributing to skyrocketing drug costs and possible solutions for impeding inflation. This years' sixth annual survey also measured the perceptions of Pharmacy Benefit Managers (PBM) for the first time.

Three out of every four respondents listed patient education about the cost effective use of a medicine as a method to lower costs. About 65 percent said educating physicians about the costs associated with prescription benefit plans would help.

"Patients and physicians can help reduce the cost of prescription benefits by constantly seeking more information on the appropriate drugs for certain health conditions. Getting the right drug to the right patient for the right condition is key to developing long term-cost control," Arxcel CEO Chris Robbins said.

Continuing to get a strong rating, 69 percent favored mail-order pharmacies as a solution for rising costs. Clinical oversight also ranked high as a possible solution, garnering support by 66 percent of those surveyed.

When respondents were asked to name the most significant cause of rising prescription costs, direct-to-consumer (DTC) advertising ranked first with 45.5 percent. Research and development (R&D) ranked second with 24.6 percent. When combined, these numbers reveal 70.1 percent of those surveyed blamed drug manufacturers for the high cost of prescription benefit programs. An aging population ranked third, with 16.8 percent.

Sixty percent of respondents said they expect an increase in prescription plan costs of up to 15 percent in the coming year. Almost half expect to pass at least part of the increase to employees.

The survey showed a split perception of the PBM industry. Half of the respondents rated the industry as "positive" or "very positive" while the other half rated it "neutral" to "very negative." While the industry received mixed reviews, individual PBMs fared somewhat better. Nearly two-thirds rated their PBM favorably with 52 percent trusting their PBM is operating in their company's best interest.

Headquartered in Williamsville, N.Y., Arxcel is a national pharmacy benefit consulting group that provides expert counsel and support in the areas of pharmacy benefits program operation and management; strategic analysis; and sales and marketing. Arxcel partners with providers of prescription drug programs to manage quality and control costs.

View the full 2007 Arxcel Prescription Benefit Research Survey at: http://www.arxcel.com/research/overview.html


'/>"/>
SOURCE Arxcel
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. S.C. BlueCross Creates Corporate Planning Unit, Promotes Davis to Vice President
2. Corporate and Political PR Pro to Lead Sudden Cardiac Arrest Association
3. DTI Medical Corporation Announces Reverse Split and Other Corporate Developments
4. Meeting Expectations Named to First Annual CMI 25 List by Corporate Meetings & Incentives Magazine
5. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
6. DSS Research Moves Corporate Office
7. The African Medical and Research Foundation (AMREF) Honors Merck & Co., Inc. with Global Corporate Philanthropy Award
8. Accuray Incorporateds CEO to Speak at UBS Global Life Sciences Conference
9. Eularis Announces New Corporate Name and Expanded Product Offerings
10. AXA Equitable Life Insurance Co. Hires William McDermott to Lead Corporate Retirement Planning Business
11. US Med-Equip Expands Corporate Support Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial ... Plant City Observer , brings up a new, often overlooked aspect of head lice: the ... closing for fumigation is not a common occurrence, but a necessary one in the event ...
(Date:6/25/2016)... , ... June 25, 2016 , ... First Choice ... States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm ... Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical ...
(Date:6/25/2016)... , ... June 25, 2016 , ... ... and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a ... area —Johnson is one of the first doctors to perform the treatment. Orthobiologics ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, ... the latter, setting the bar too high can result in disappointment, perhaps even self-loathing. ... toward their goal. , Research from PsychTests.com reveals that behind the ...
(Date:6/24/2016)... ... , ... Those who have experienced traumatic events may suffer from a complex ... as drug or alcohol abuse, as a coping mechanism. To avoid this pain and ... a traumatic event. , Trauma sufferers tend to feel a range of emotions, from ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Global MEMS Devices Medical Market Analysis 2016 - Forecast to ... The report contains up to date financial ... reliable analysis. Assessment of major trends with potential impact on ... dive analysis of market segmentation which comprises of sub markets, ...
(Date:6/23/2016)... , June 23, 2016 Research ... Pharma News Issue 52" report to their offering. ... in influenza treatment creates a favourable commercial environment for MedImmune ... growing patient base that will serve to drive considerable growth ... vaccine would serve to cap sales considerably, but development is ...
(Date:6/23/2016)... , , , WHEN: ... , , , , LOCATION: , , , Online, with ... , EXPERT PANELISTS:  , , , Frost & Sullivan,s Global Vice ... Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, Program Manager , ... industry is witnessing an exceptional era. Several new demand spaces, such ...
Breaking Medicine Technology: